Acamprosate produces its anti-relapse effects via calcium

Neuropsychopharmacology

Volumn 39, Issue 4, 2014, Pages 783-791

  Spanagel, Rainer ^a   Vengeliene, Valentina ^a   Jandeleit, Bernd ^b   Fischer, Wolf Nicolas ^b   Grindstaff, Kent ^b   Zhang, Xuexiang ^b   Gallop, Mark A ^b   Krstew, Elena V ^c   Lawrence, Andrew J ^c   Kiefer, Falk ^d  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b XenoPort Inc   (United States)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

Author keywords

alcohol addiction; alcohol deprivation effect; alcohol preferring rats; clinical trial acamprosate; glutamate; translational alcohol research

Indexed keywords

ALCOHOL DETERRENTS; ALCOHOLISM; ANIMALS; CALCIUM; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID AGENTS; EXCITATORY POSTSYNAPTIC POTENTIALS; GABA AGENTS; HUMANS; MALE; MEMBRANE POTENTIALS; PATCH-CLAMP TECHNIQUES; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECEPTORS, N-METHYL-D-ASPARTATE; RECURRENCE; TAURINE; XENOPUS LAEVIS;

EID: 84894084878     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2013.264     Document Type: Article

References (46)

1. Bachteler D, Economidou D, Danysz W, Ciccocioppo R, Spanagel R (2005). The effects of acamprosate and neramexane on cueinduced reinstatement of ethanol-seeking behavior in rat. Neuropsychopharmacology 30: 1104-1110.
2. Bell RL, Rodd ZA, Lumeng L, Murphy JM, McBride WJ (2006). The alcohol-preferring P rat and animal models of excessive alcohol drinking. Addict Biol 11: 270-288.
3. Boismare F, Daoust M, Moore N, Saligaut C, Lhuintre JP, Chretien P et al (1984). A homotaurine derivative reduces the voluntary intake of ethanol by rats: are cerebral GABA receptors involved? Pharmacol Biochem Behav 21: 787-789.
4. Chabenat C, Chretien P, Daoust M, Moore N, Andre D, Lhuintre JP et al (1988). Physicochemical, pharmacological and pharmacokinetic study of a new GABAergic compound, calcium acetylhomotaurinate. Methods Find Exp Clin Pharmacol 10: 311-317.
5. Chau P, Hoifodt-Lido H, Lof E, Soderpalm B, Ericson M (2010a). Glycine receptors in the nucleus accumbens involved in the ethanol intake-reducing effect of acamprosate. Alcohol Clin Exp Res 34: 39-45.
6. Chau P, Stomberg R, Fagerberg A, Soderpalm B, Ericson M (2010b). Glycine receptors involved in acamprosate's modulation of accumbal dopamine levels: an in vivo microdialysis study. Alcohol Clin Exp Res 34: 32-38.
7. Cowen MS, Adams C, Kraehenbuehl T, Vengeliene V, Lawrence AJ (2005). The acute anti-craving effect of acamprosate in alcoholpreferring rats is associated with modulation of the mesolimbic dopamine system. Addict Biol 10: 233-242.
8. De Witte P, Littleton J, Parot P, Koob G (2005). Neuroprotective and abstinence-promoting effects of acamprosate: elucidating the mechanism of action. CNS Drugs 19: 517-537.
9. Emsley CL, Gao S, Li Y, Liang C, Ji R, Hall KS et al (2000). Trace element levels in drinking water and cognitive function among elderly Chinese. Am J Epidemiol 151: 913-920.
10. Erickson CK, Tyler TD, Harris RA (1978). Ethanol: modifications of acute intoxication by divalent cations. Science 199: 1219-1221.
11. Harris BR, Prendergast MA, Gibson DA, Rogers DT, Blanchard JA, Holley RC et al (2002). Acamprosate inhibits the binding and neurotoxic effects of trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors. Alcohol Clin Exp Res 26: 1779-1793.
12. Heyser CJ, Schulteis G, Durbin P, Koob GF (1998). Chronic acamprosate eliminates the alcohol deprivation effect while having limited effects on baseline responding for ethanol in rats. Neuropsychopharmacology 18: 125-133.
13. Hopf FW, Simms JA, Chang SJ, Seif T, Bartlett SE, Bonci A (2011). Chlorzoxazone, an SK-type potassium channel activator used in humans, reduces excessive alcohol intake in rats. Biol Psychiatry 69: 618-624.
14. Kiefer F, Jahn H, Tarnaske T, Helwig H, Briken P, Holzbach R et al (2003). Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebocontrolled study. Arch Gen Psychiatry 60: 92-99.
15. Kosinski CM, Standaert DG, Counihan TJ, Scherzer CR, Kerner JA, Daggett LP et al (1998). Expression of N-methyl-D-aspartate receptor subunit mRNAs in the human brain: striatum and globus pallidus. J Comp Neurol 390: 63-74.
16. Lido HH, Marston H, Ericson M, Soderpalm B (2012). The glycine reuptake inhibitor Org24598 and acamprosate reduce ethanol intake in the rat; tolerance development to acamprosate but not to Org24598. Addict Biol 17: 897-907.
17. Litten RZ, Egli M, Heilig M, Cui C, Fertig JB, Ryan ML et al (2012). Medications development to treat alcohol dependence: a vision for the next decade. Addict Biol 17: 513-527.
18. Lynch MA, Littleton JM (1983). Possible association of alcohol tolerance with increased synaptic Ca2+ sensitivity. Nature 303: 175-176.
19. Madamba SG, Schweitzer P, Zieglgansberger W, Siggins GR (1996). Alcohol Clin Exp Res 20: 651-658.
20. Mann K, Kiefer F, Spanagel R, Littleton J (2008). Acamprosate: recent findings and future research directions. Alcohol Clin Exp Res 32: 1105-1110.
21. Mann K, Bladstrom A, Torup L, Gual A, van den Brink W (2013). Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene. Biol Psychiatry 73: 706-713.
22. Mark TL, Kassed CA, Vandivort-Warren R, Levit KR, Kranzler HR (2009). Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty. Drug Alcohol Depend 99: 345-349.
23. Mason BJ, Heyser CJ (2010). Acamprosate: a prototypic neuromodulator in the treatment of alcohol dependence. CNS Neurol Disord Drug Targets 9: 23-32.
24. Mulholland PJ, Becker HC, Woodward JJ, Chandler LJ (2011). Small conductance calcium-activated potassium type 2 channels regulate alcohol-associated plasticity of glutamatergic synapses. Biol Psychiatry 69: 625-632.
25. 0'Brien CC (1952). Experimental evidence in the treatment of alcoholism by intensive calcium therapy. J Am Osteopath Assoc 51: 393-394.
26. O'Brien CC (1964). Intensive calcium therapy as an initial approach to the psychotherapeutic relationship in the rehabilitation of the compulsive drinker. J Psychol 57: 125-129.
27. Rammes G, Mahal B, Putzke J, Parsons C, Spielmanns P, Pestel E et al (2001). The anti-craving compound acamprosate acts as a weak NMDA-receptor antagonist, but modulates NMDA-receptor subunit expression similar to memantine and MK-801. Neuropharmacology 40: 749-760.
28. Reilly MT, Lobo IA, McCracken LM, Borghese CM, Gong D, Horishita T et al (2008). Effects of acamprosate on neuronal receptors and ion channels expressed in Xenopus oocytes. Alcohol Clin Exp Res 32: 188-196.
29. Rehm J, Mathers C, Popova S, Thavorncharoensap M, Teerawattananon Y, Patra J (2009). Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet 373: 2223-2233.
30. Rosner S, Hackl-Herrwerth A, Leucht S, Lehert P, Vecchi S, Soyka M (2010). Acamprosate for alcohol dependence. Cochrane Database Syst Rev 8: CD004332.
31. Sanchis-Segura C, Spanagel R (2006). Behavioural assessment of drug-reinforcement and addictive features in rodents: an overview. Addict Biol 11: 2-38.
32. Scherzer CR, Landwehrmeyer GB, Kerner JA, Counihan TJ, Kosinski CM, Standaert DG et al (1998). Expression of N-methyl-D-aspartate receptor subunit mRNAs in the human brain: hippocampus and cortex. J Comp Neurol 390: 75-90.
33. Shaham Y, Shalev U, Lu L, De Wit H, Stewart J (2003). The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology (Berl) 168: 3-20.
34. Spanagel R, Holter SM, Allingham K, Landgraf R, Zieglgansberger W (1996a). Acamprosate and alcohol: I. Effects on alcohol intake following alcohol deprivation in the rat. Eur J Pharmacol 305: 39-44.
35. Spanagel R, Putzke J, Zieglgansberger W, Stefferl A, Schobitz B (1996b). Acamprosate and alcohol: II. Effects on alcohol withdrawal in the rat. Eur J Pharmacol 305: 45-50.
36. Spanagel R, Pendyala G, Abarca C, Zghoul T, Sanchis-Segura C, Magnone MC et al (2005). The clock gene Per2 influences the glutamatergic system and modulates alcohol consumption. Nat Med 11: 35-42.
37. Spanagel R, Kiefer F (2008). Drugs for relapse prevention of alcoholism: ten years of progress. Trends Pharmacol Sci 29: 109-115.
38. Spanagel R (2009). Alcoholism: a systems approach from molecular physiology to addictive behavior. Physiol Rev 89: 649-705.
39. Spanagel R, Bartsch D, Brors B, Dahmen N, Deussing J, Eils R et al (2010). An integrated genome research network for studying the genetics of alcohol addiction. Addict Biol 15: 369-379.
40. Spanagel R, Vengeliene V (2013). New pharmacological treatment strategies for relapse prevention. Curr Top Behav Neurosci 13: 583-609.
41. Stutzmann GE (2007). The pathogenesis of Alzheimers disease is it a lifelong calciumopathy'? Neuroscientist 13: 546-559.
42. Tsai G, Gastfriend DR, Coyle JT (1995). The glutamatergic basis of human alcoholism. Drugs for relapse prevention of alcoholism: ten years of progress. Am J Psychiatry 152: 332-340.
43. Umhau JC, Momenan R, Schwandt ML, Singley E, Lifshitz M, Doty L et al (2010). Effect of acamprosate on magnetic resonance spectroscopy measures of central glutamate in detoxified alcohol-dependent individuals: a randomized controlled experimental medicine study. Arch Gen Psychiatry 67: 1069-1077.
44. Umhau JC, Schwandt ML, Usala J, Geyer C, Singley E, George DT et al (2011). Pharmacologically induced alcohol craving in treatment seeking alcoholics correlates with alcoholism severity, but is insensitive to acamprosate. Neuropsychopharmacology 36: 1178-1186.
45. Vengeliene V, Celerier E, Chaskiel L, Penzo F, Spanagel R (2009). Compulsive alcohol drinking in rodents. Addict Biol 14: 384-396.
46. Zeise ML, Kasparov S, Capogna M, Zieglgansberger W (1993). Acamprosate (calciumacetylhomotaurinate) decreases postsynaptic potentials in the rat neocortex: possible involvement of excitatory amino acid receptors. Eur J Pharmacol 231: 47-52.